802 related articles for article (PubMed ID: 22193346)
21. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up].
Ishida H; Matsuo S; Inoue Y
Rinsho Byori; 2010 Nov; 58(11):1065-72. PubMed ID: 21229703
[TBL] [Abstract][Full Text] [Related]
23. Clinical application of determining serum AFP-IgM complexes for diagnosis of small hepatocellular carcinoma.
Jiang J; Wu C; Shen Y; Xu B; Zheng X; Li X; Xu N
Anticancer Res; 2011 Feb; 31(2):687-91. PubMed ID: 21378357
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.
Mossad NA; Mahmoud EH; Osman EA; Mahmoud SH; Shousha HI
Tumour Biol; 2014 Nov; 35(11):11559-64. PubMed ID: 25129443
[TBL] [Abstract][Full Text] [Related]
25. Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels.
Bertino G; Ardiri AM; Santonocito MM; Boemi PM
Panminerva Med; 2009 Jun; 51(2):133-4. PubMed ID: 19776714
[No Abstract] [Full Text] [Related]
26. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC).
Pozzan C; Cardin R; Piciocchi M; Cazzagon N; Maddalo G; Vanin V; Giacomin A; Pontisso P; Cillo U; Farinati F
J Gastroenterol Hepatol; 2014 Aug; 29(8):1637-44. PubMed ID: 24635038
[TBL] [Abstract][Full Text] [Related]
27. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
[TBL] [Abstract][Full Text] [Related]
28. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
Izuno K; Fujiyama S; Yamasaki K; Sato M; Sato T
Hepatogastroenterology; 1995; 42(4):387-93. PubMed ID: 8586374
[TBL] [Abstract][Full Text] [Related]
29. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
[TBL] [Abstract][Full Text] [Related]
30. Serum markers of hepatocellular carcinoma.
Spangenberg HC; Thimme R; Blum HE
Semin Liver Dis; 2006 Nov; 26(4):385-90. PubMed ID: 17051452
[TBL] [Abstract][Full Text] [Related]
31. New serum markers of hepatocellular carcinoma.
Masuzaki R; Karp SJ; Omata M
Semin Oncol; 2012 Aug; 39(4):434-9. PubMed ID: 22846860
[TBL] [Abstract][Full Text] [Related]
32. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients.
Giannelli G; Fransvea E; Trerotoli P; Beaugrand M; Marinosci F; Lupo L; Nkontchou G; Dentico P; Antonaci S
Clin Chim Acta; 2007 Aug; 383(1-2):147-52. PubMed ID: 17582392
[TBL] [Abstract][Full Text] [Related]
33. Coagulation assays as diagnostic markers of hepatocellular carcinoma.
Lefrère JJ; Conard J; Mavier P; Bettan L; Beaugrand M; Gozin D; Lerable J; Dhumeaux D; Samama M
Thromb Haemost; 1988 Dec; 60(3):468-70. PubMed ID: 2467402
[TBL] [Abstract][Full Text] [Related]
34. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
[TBL] [Abstract][Full Text] [Related]
35. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
Toyoda H; Kumada T; Kaneoka Y; Osaki Y; Kimura T; Arimoto A; Oka H; Yamazaki O; Manabe T; Urano F; Chung H; Kudo M; Matsunaga T
J Hepatol; 2008 Aug; 49(2):223-32. PubMed ID: 18571271
[TBL] [Abstract][Full Text] [Related]
37. [Surveillance of cirrhosis for hepatocellular carcinoma--clinical validation of new serological biomarkers for improved diagnosis].
Teofănescu I; Gologan E; Stefănescu G; Bălan G
Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):39-46. PubMed ID: 20509274
[TBL] [Abstract][Full Text] [Related]
38. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
Tateishi R; Shiina S; Yoshida H; Teratani T; Obi S; Yamashiki N; Yoshida H; Akamatsu M; Kawabe T; Omata M
Hepatology; 2006 Dec; 44(6):1518-27. PubMed ID: 17133456
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
40. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
